FDA Raises Bar for Comparability Studies after Approval
This article was originally published in The Gold Sheet
Executive Summary
FDA sets a higher bar for approving comparability studies for biotech drugs once they have been approved for marketing than for the preapproval stage, but the regulatory expectations are clearer, said an agency official. Representatives of the biopharmaceutical industry also advised manufacturers to take a risk-based approach to assess comparability and outlined some methods that can be used to ensure that modifications do not affect drug safety and effectiveness.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.